$CERC News

Last published 5y ago

5y agoAVTX CERCAvalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.GlobeNewswireName change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases Robust pipeline of six product candidates advancing in development with eight ongoing clinical progra
5y agoCERCCerecor Reports Second Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireAnnounced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Announced plans to explore CE
5y agoCERC HRZNCerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology FinanceGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and ra
5y agoADTX CERC EYEG MOGU+1Thinking about buying stock in Eyegate Pharmaceuticals, Mogu, Aditxt, Powerbridge Technologies, or Cerecor?PR NewswireNEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EYEG, MOGU, ADTX, PBTS, and CERC.
5y agoCERCCerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsGlobeNewswirePositive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Mean reduction in LIGHT levels of appro
5y agoCERCCerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology TargetsGlobeNewswireROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, to
5y agoCERC HRZNCerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology FinanceGlobeNewswireAn initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candidates Financing provides flexibility and extends runway through multiple clinical catalysts expected in 2021 ROCKVIL
5y agoCERC ELOX LPTH NERV+1Thinking about buying stock in LightPath Technologies, Minerva Neurosciences, Cerecor, Eloxx Pharmaceuticals, or Soleno Therapeutics?PR NewswireNEW YORK, May 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTH, NERV, CERC, ELOX, and SLNO. T
5y agoCERCCerecor to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today annou
5y agoCERCCerecor Reports First Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireAnnounced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS Secured exclusive, world-wide rights to develop, manu
5y agoCERC PLTR SOS SPCE+1Thinking about buying stock in Palantir Technologies, Cerecor, Virgin Galactic, SOS, or Zomedica?PR NewswireNEW YORK, May 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, CERC, SPCE, SOS, and ZOM. To
5y agoCERCFDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19GlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced
5y agoCERCCerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still's DiseaseGlobeNewswireInitial data anticipated in the third quarter of 2021 Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021 ROCKVILLE, Md. and
5y agoCERCCerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002GlobeNewswireExpanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS...
5y agoCERCCerecor Reports 2020 Financial Results and Provides Business UpdatesGlobeNewswire•Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS •Improved financial position with $18.9M of cash on...
5y agoCERCCerecor to Present at Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and...
5y agoCERCCerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDSGlobeNewswireFinal analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day...
5y agoCERCCerecor Appoints Schond L. Greenway as Chief Financial OfficerGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
5y agoCERCA Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease - NCT04752371ClinicalTrials.govIncidence of Treatment Emergent Adverse Events (TEAEs), Incidence of Clinically Significant Changes from Baseline in Vital Signs, Incidence of Clinically Significant Changes from Baseline in Clinical Laboratory Results, (and 18 more...)
5y agoCERCCerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type IIGlobeNewswireROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
5y agoCERCCerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 MillionGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and...
5y agoCERCCerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDSGlobeNewswireCOVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of...
5y agoCERCCerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s DiseaseGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple MyelomaGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple MyelomaGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type IIGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
5y agoCERCCerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDGGlobeNewswireROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
6y agoCERCCerecor Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireOn track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the appointment of Gilla Kaplan, Ph.D., to the Board of...
6y agoCERCCerecor Appoints Gilla Kaplan, Ph.D., to the Board of DirectorsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
6y agoCERCCerecor to Present at Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
6y agoCERCCerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s DiseaseGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
6y agoCERCCerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDSGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
6y agoCERCCerecor Reports Second Quarter 2020 Financial Results and Business UpdateGlobeNewswire-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the...
6y agoCERCCerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric...
6y agoCERCCerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic MalformationsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
6y agoCERCCerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic MalformationsGlobeNewswireROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
6y agoCERCCerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDSGlobeNewswireROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
6y agoCERCCerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional SharesGlobeNewswireROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
6y agoCERCCerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common StockGlobeNewswireROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
6y agoCERCCerecor Inc. Announces Proposed Public Offering of Common StockGlobeNewswireROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
6y agoCERCCerecor to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewswireROCKVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies Virtual...
6y agoCERCCerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDSGlobeNewswireCompany to Initiate Multicenter, Placebo-controlled, Randomized Study in JuneTop-line Data Anticipated in Fourth Quarter 2020 ROCKVILLE, Md., May 28, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:...
6y agoCERCCerecor Reports Q1 2020 Results and UpdateGlobeNewswireSignificantly Improved Cash Position and Balance SheetClosed Aevi Merger; Transformed into Orphan and Rare Disease Biotech ROCKVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:...
6y agoCERCCerecor Announces Changes to Board of DirectorsGlobeNewswire-Appoints Sol J. Barer, Ph.D. as Chairman of the Board- Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc....
6y agoCERCCerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress SyndromeGlobeNewswireROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
6y agoCERCCerecor Reports 2019 ResultsGlobeNewswire-Company Transformed Into Orphan and Rare Disease Biotech-Clear Corporate Strategy with New Leadership-Significant Advancement in Pipeline and Regulatory Milestones ROCKVILLE, Md., March 11, 2020 ...
6y agoCERCCerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development OfficerGlobeNewswireROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...